“We are thrilled to receive approval from Health Canada for the use of Remsima™ SC as a maintenance therapy for patients with ulcerative colitis and Crohn’s disease,” said Dr. HoUng Kim, Head of Medical and Marketing Division at Celltrion Healthcare. “This approval further expands the treatment options available for Canadians living with these chronic and debilitating conditions.”
Ulcerative colitis and Crohn’s disease are chronic inflammatory bowel diseases that can significantly impact the quality of life of those affected. With the approval of Remsima™ SC, patients now have access to a subcutaneous formulation of infliximab that can be administered at home, offering greater convenience and flexibility in managing their condition.
The approval of Remsima™ SC for maintenance therapy in UC and CD comes after the successful launch of the drug for the treatment of rheumatoid arthritis in Canada. Remsima™ SC is a biosimilar to the reference product Remicade® and was developed to provide a more convenient and accessible treatment option for patients with autoimmune and inflammatory diseases.
In addition to the LIBERTY UC and LIBERTY CD clinical trials, the approval of Remsima™ SC was also supported by real-world evidence, which showed consistent and effective results in the treatment of patients with ulcerative colitis and Crohn’s disease. This real-world evidence further demonstrates the safety and efficacy of the subcutaneous form of infliximab in a broader patient population.
As a magazine editor, it is important to provide readers with accurate and relevant information about the latest advancements in healthcare. The approval of Remsima™ SC for maintenance therapy in UC and CD is a significant development in the field of gastroenterology and autoimmune diseases. This approval expands the treatment options available to patients in Canada, offering a more convenient and accessible form of infliximab for managing their condition.
Readers can feel confident in the safety and efficacy of Remsima™ SC, knowing that it was approved by Health Canada based on rigorous clinical evidence and real-world data. This approval reflects the commitment of Celltrion Healthcare to improving the lives of patients with chronic and debilitating diseases, and highlights the potential impact of biosimilars in providing more affordable and accessible treatment options.
In conclusion, the approval of Remsima™ SC for maintenance therapy in ulcerative colitis and Crohn’s disease is a significant milestone for patients and healthcare providers in Canada. It represents a step forward in expanding treatment options for those living with chronic inflammatory bowel diseases, and offers greater convenience and flexibility in managing their condition. Patients can now look forward to a more convenient and accessible form of infliximab therapy, thanks to the approval of Remsima™ SC by Health Canada.
